Home > Cardiology > ESC 2021 > Edoxaban non-inferior to vitamin K antagonist in TAVI patients

Edoxaban non-inferior to vitamin K antagonist in TAVI patients

Presented By
Prof. George Dangas, Mount Sinai Hospital, USA
Conference
ESC 2021
Trial
ENVISAGE-TAVI AF
Anticoagulation strategies for atrial fibrillation (AF) with either edoxaban or vitamin K antagonists (VKA) were evaluated in patients post transcatheter aortic valve implantation (TAVI) in the ENVISAGE-TAVI AF trial. Edoxaban demonstrated non-inferiority in Net Adverse Clinical Events (NACE); however, due to a higher rate of major bleeding, there was no non-inferiority in the safety outcome [1]. ENVISAGE-TAVI AF (NCT02943785) is a prospective randomised, open-label, blinded trial comparing edoxaban to VKA in AF patients with indication for chronic anticoagulation therapy after TAVI. The primary efficacy outcome was defined as NACE, comprising components such as all-cause death, myocardial infarction, or ischaemic stroke. An additional primary safety outcome was major bleeding as defined by the International Society on Thrombosis and Haemostasis (I...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on